Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPC

Luke Nordquist, MD
Published: Friday, Sep 16, 2016


Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.
 
Radium-223 is currently approved at 50 kBq/kg monthly for 6 months in mCRPC. The study examined 44 patients who received an additional 6 doses of radium-223, and found that only 1 patient had confirmed radiographic progression.
 
Whether or not there is a therapeutic benefit is yet to be determined, says Nordquist.
 
Bayer is sponsoring a 3-arm study in which patients are assigned to the standard 50-kBq/kg dose for 6 doses, a higher dose of 80 kBq/kg for 6 doses, or the 50 kBq/kg dose for 12 doses. This will help provide us additional information of that topic.  
 

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.
 
Radium-223 is currently approved at 50 kBq/kg monthly for 6 months in mCRPC. The study examined 44 patients who received an additional 6 doses of radium-223, and found that only 1 patient had confirmed radiographic progression.
 
Whether or not there is a therapeutic benefit is yet to be determined, says Nordquist.
 
Bayer is sponsoring a 3-arm study in which patients are assigned to the standard 50-kBq/kg dose for 6 doses, a higher dose of 80 kBq/kg for 6 doses, or the 50 kBq/kg dose for 12 doses. This will help provide us additional information of that topic.  
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x